Scholarlink

Background <p>Growth hormone deficiency (GHD) requires long-term hormone replacement therapy, most commonly through daily injections of recombinant human growth hormone (rhGH). Although effective, this daily regimen may lead to poor adherence, particularly in children. Somapacitan, a long-acting growth hormone analog administered once weekly, has emerged as a potential alternative. This systematic review and meta-analysis compares the efficacy, safety, and biochemical outcomes of once-weekly somapacitan with daily Norditropin in patients with GHD.</p> Methods <p>Following PRISMA guidelines (PROSPERO: CRD420251118208), PubMed and CENTRAL were systematically searched up to August 2025. Randomized controlled trials comparing somapacitan with Norditropin in patients with GHD were included. Data were pooled using a random-effects meta-analysis in Review Manager 5.4, and risk of bias was assessed using the Cochrane RoB 2 tool.</p> Results <p>Ten randomized controlled trials involving 920 participants were included. Somapacitan and Norditropin demonstrated comparable outcomes in height velocity (MD = 0.12; 95% CI − 0.65–0.89; <i>p</i> = 0.76) and height SDS (MD = − 0.04; 95% CI − 1.02–0.93; <i>p</i> = 0.94). Safety profiles were also similar (RR = 1.03; 95% CI 0.88–1.20; <i>p</i> = 0.70), with no significant differences in immunogenicity or adverse events. However, somapacitan showed a modest improvement in IGF-1 SDS (MD = 0.24; 95% CI 0.02–0.46; <i>p</i> = 0.04).</p> Conclusion <p>Once-weekly somapacitan demonstrates comparable efficacy and safety to daily Norditropin while offering greater convenience that may improve treatment adherence. These findings support somapacitan as a promising therapeutic option for patients with GHD, although long-term real-world studies are needed to confirm sustained benefits in growth outcomes, metabolic health, and quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Once-weekly somapacitan vs. daily norditropin in GHD: a systematic review and meta-analysis of efficacy and safety in children and adults

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Sarah Azhar,
  • Mohammad Daniyal,
  • Roshni Riaz Memon,
  • Hamza Sajid,
  • Nad e Ali Yousfani,
  • Hamza Yousuf Ibrahim,
  • Syeda Umme Farwa,
  • Shaharyar Ahmed,
  • Mohsin Ali,
  • Rimsha Abbas,
  • Syed Muhammad Abbas,
  • Ahmed Ali Khan,
  • Haider Imran

摘要

Background

Growth hormone deficiency (GHD) requires long-term hormone replacement therapy, most commonly through daily injections of recombinant human growth hormone (rhGH). Although effective, this daily regimen may lead to poor adherence, particularly in children. Somapacitan, a long-acting growth hormone analog administered once weekly, has emerged as a potential alternative. This systematic review and meta-analysis compares the efficacy, safety, and biochemical outcomes of once-weekly somapacitan with daily Norditropin in patients with GHD.

Methods

Following PRISMA guidelines (PROSPERO: CRD420251118208), PubMed and CENTRAL were systematically searched up to August 2025. Randomized controlled trials comparing somapacitan with Norditropin in patients with GHD were included. Data were pooled using a random-effects meta-analysis in Review Manager 5.4, and risk of bias was assessed using the Cochrane RoB 2 tool.

Results

Ten randomized controlled trials involving 920 participants were included. Somapacitan and Norditropin demonstrated comparable outcomes in height velocity (MD = 0.12; 95% CI − 0.65–0.89; p = 0.76) and height SDS (MD = − 0.04; 95% CI − 1.02–0.93; p = 0.94). Safety profiles were also similar (RR = 1.03; 95% CI 0.88–1.20; p = 0.70), with no significant differences in immunogenicity or adverse events. However, somapacitan showed a modest improvement in IGF-1 SDS (MD = 0.24; 95% CI 0.02–0.46; p = 0.04).

Conclusion

Once-weekly somapacitan demonstrates comparable efficacy and safety to daily Norditropin while offering greater convenience that may improve treatment adherence. These findings support somapacitan as a promising therapeutic option for patients with GHD, although long-term real-world studies are needed to confirm sustained benefits in growth outcomes, metabolic health, and quality of life.